Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure-based development of a subtype-selective orexin 1 receptor antagonist
Jan Hellmann, Matthäus Drabek, Jie Yin, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 30, pp. 18059-18067
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?
Flavio Ballante, Albert J. Kooistra, Stefanie Kampen, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1698-1736
Open Access | Times Cited: 104
Structure-based discovery of nonopioid analgesics acting through the α 2A -adrenergic receptor
Elissa A. Fink, Jun Xu, Harald Hübner, et al.
Science (2022) Vol. 377, Iss. 6614
Open Access | Times Cited: 101
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Art and Science of Molecular Docking
Joseph M. Paggi, Ayush Pandit, Ron O. Dror
Annual Review of Biochemistry (2024) Vol. 93, Iss. 1, pp. 389-410
Closed Access | Times Cited: 58
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development
Jennifer Kricker, Clive P. Page, Fridrik Runar Gardarsson, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1404-1433
Open Access | Times Cited: 58
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Membrane protein production and formulation for drug discovery
Ellen Gulezian, Christina Crivello, Janna Bednenko, et al.
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 8, pp. 657-674
Closed Access | Times Cited: 47
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief
Alan Hégron, Chloe J. Peach, Raquel Tonello, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 22
Open Access | Times Cited: 19
Discovery of 2-Aminopyrimidines as Potent Agonists for the Bitter Taste Receptor TAS2R14
Lukas Waterloo, Harald Hübner, Fabrizio Fierro, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3499-3521
Closed Access | Times Cited: 17
Advances in structure-based drug design: The potential for precision therapeutics in psychiatric disorders
Dongmei Cao, Pei Zhang, Sheng Wang
Neuron (2024) Vol. 112, Iss. 4, pp. 526-538
Closed Access | Times Cited: 6
Molecular mechanism of the wake-promoting agent TAK-925
Jie Yin, Yanyong Kang, Aaron P. McGrath, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics
Xinyu Xu, Jeremy Shonberg, Jonas Kaindl, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models
Oshin Miranda, Peihao Fan, Xiguang Qi, et al.
Drug and Alcohol Dependence (2024) Vol. 255, pp. 111066-111066
Open Access | Times Cited: 5
Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer’s disease and Parkinson’s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)
Siva Prasad Panda, Suman Sinha, Adarsh Kesharwani, et al.
Biochemical Pharmacology (2025), pp. 116794-116794
Closed Access
Parishin A alleviates insomnia by regulating hypothalamic-pituitary-adrenal axis homeostasis and directly targeting orexin receptor OX2
Lijing Zhang, Ya-Ru Zhao, Liqiao Chen, et al.
European Journal of Pharmacology (2025), pp. 177498-177498
Closed Access
Leveraging nonstructural data to predict structures and affinities of protein–ligand complexes
Joseph M. Paggi, Julia A. Belk, Scott A. Hollingsworth, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 51
Open Access | Times Cited: 27
Interaction modes of human orexin 2 receptor with selective and nonselective antagonists studied by NMR spectroscopy
Kayo Imamura, Ken‐ichi Akagi, Yohei Miyanoiri, et al.
Structure (2024) Vol. 32, Iss. 3, pp. 352-361.e5
Open Access | Times Cited: 2
Structure-guided discovery of orexin receptor-binding PET ligands
Katharina Distler, Simone Maschauer, Eduard Neu, et al.
(2024)
Open Access | Times Cited: 2
Structure-guided discovery of orexin receptor-binding PET ligands
Katharina Distler, Simone Maschauer, Eduard Neu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117823-117823
Open Access | Times Cited: 2
The transmembrane domains of GPCR dimers as targets for drug development
Xin Cai, Dexiu Wang, Rumin Zhang, et al.
Drug Discovery Today (2022) Vol. 28, Iss. 1, pp. 103419-103419
Closed Access | Times Cited: 12
Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target
Alain Couvineau, Nicole Pascal, Gratio Valérie, et al.
Molecules (2021) Vol. 26, Iss. 16, pp. 4849-4849
Open Access | Times Cited: 15
Abolishing Dopamine D2long/D3 Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H2 Receptor Agonists
Katharina Tropmann, Merlin Bresinsky, Lisa Forster, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8684-8709
Closed Access | Times Cited: 12
Computational Analysis of Fully Activated Orexin Receptor 2 Across Various Thermodynamic Ensembles with Surface Tension Monitoring
Rafael Doležal
(2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top